成人急性髓性白血病的门因抑制剂:2025年更新
Umar Iqbal1, Julia Fadul1, David A Sallman1
1Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USA.
Expert opinion on investigational drugs
|December 31, 2025
概括
梅宁抑制剂通过向特定基因相互作用,在治疗急性髓性白血病 (AML) 中表现有前途. 这些药物正在扩大其使用范围,但仔细监测对于患者安全和治疗成功至关重要.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 梅宁抑制剂代表了一种针对梅宁-KMT2A相互作用的新型治疗类.
- 这种机制在特定的急性髓性白血病 (AML) 亚组中至关重要,由HOXA9/MEIS1通路过度表达驱动.
- 患有这些AML亚组的患者面临着不良预后,特别是在复发/耐药病例中.
研究的目的:
- 审查阴阴抑制剂的阴阴病生物学和当前的临床数据.
- 讨论临床细微差别,新兴应用和这种药物类别的未满足需求.
- 为未来的研究和发展提供洞察力 脑膜抑制剂.
主要方法:
- 使用PubMed/MEDLINE,Embase和Web of Science进行了全面的文献搜索.
- 搜索包括到2025年8月25日发表的文章,使用与"阴抑制剂"相关的关键词.
- 还审查了会议摘要和临床试验注册表.
主要成果:
- 梅因抑制剂的使用正在扩展到其他HOX驱动的AML亚型 (例如,NPM1,NUP98r).
- 这些抑制剂正在被探索为前线选择和组合疗法.
- 关键考虑因素包括对分化综合征,QT延长和伪进展的监测.
结论:
- 阴膜抑制剂为特定的AML群体提供了一种新的治疗途径.
- 仔细的患者监测和支持性护理对于优化结果至关重要.
- 需要进一步的研究,以解决目前未得到满足的脑膜抑制剂治疗需求.
相关概念视频
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:50Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
02:34Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
01:15Drugs that Stabilize Microtubules
2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K